A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IXORA-P
- Sponsors Eli Lilly
- 21 Jul 2017 Trial has been completed in Poland.
- 21 Jun 2017 Trial has been completed in Hungary. (End date: 2017-04-20).
- 07 May 2017 Trial has been completed in Czech Republic